2026年9月12日-18日，全球医药市场共签署了21项资产授权和合作协议。中国市场共达成8项交易，包括5项出海交易、1项引进交易和2项国内交易。
中国市场，本周最大的出海交易是诺华行使独家选择权收购维泰瑞隆专有脑部递送平台的全球权益，首付款1.25亿美元，总金额可达1.75亿美元。
中国以外市场，本周共签署了13项资产授权和合作协议。最大的交易是DualitasTherapeutics与Roche达成研究合作和许可协议，使用Dualitas的DualScreen™双特异性发现引擎，开发用于免疫学和炎性（I&I）疾病的新型双特异性抗体，首付款3,650万美元，总金额可达10亿美元。
From September 12 to 18, a total of 21 biopharmaceutical licensing and collaboration transactions were announced globally. Of these, eight were China-related, defined as transactions involving at least one China-based company. These comprised five out-licensing deals, one in-licensing deal, and two domestic partnerships.
In China, the largest transaction involved Sironax and Novartis for a preclinical brain delivery module platform, with an upfront payment of $125 million and a total deal value of $175 million.
Outside China, 13 deals were announced. The largest transaction involved Dualitas Therapeutics and Roche to advance novel bispecific antibodies for immunology and inflammation (I&I) diseases using Dualitas’ DualScreen™ Bispecific Discovery Engine, with an upfront payment of $36.5 million and a potential total deal value of up to $1 billion.
3. M&A Deals
4. Top Deals of 2026
